Business Context and Reporting Period
This Form 8-K Current Report was filed by Amphastar Pharmaceuticals, Inc. on August 1, 2016, with the earliest event reported on the same date. The filing details a strategic acquisition executed through the company's wholly-owned UK subsidiary, Amphastar UK Limited.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The only specific financial figure disclosed relates to the transaction consideration.
- Acquisition Consideration: $7.7 million in cash (minus certain expenses).
Material Changes
The primary material change is the acquisition of International Medication Systems (UK) Limited ("IMS UK"), a subsidiary of UCB PHARMA GmbH. Key details of this transaction include:
- Assets Acquired: Product trademarks, related product assets, and Marketing Authorizations for 33 products across the UK, Ireland, Australia, and New Zealand.
- Product Scope: The portfolio represents 11 different injectable chemical entities.
- Regulatory Status: The transfer requires approval from the UK MHRA and other related regulatory agencies before the products can be re-launched.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of general risks. The primary contingency noted is the regulatory approval process required to re-launch the acquired products.
Investor Verification Checklist
- Verify the final closing date and any adjustments to the $7.7 million cash consideration.
- Monitor the status of UK MHRA and other regulatory approvals required for the 33 acquired products.
- Review the attached Press Release (Exhibit 99.1) for additional details on the strategic rationale and product portfolio.
- Confirm the timeline for the re-launch of the injectable chemical entities in the target markets.